CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Capricor Therapeutics Inc (CAPR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including overwhelmingly positive Phase 3 trial results for its lead therapy Deramiocel, multiple analyst upgrades with significantly raised price targets, and a high probability of FDA approval by mid-2026. Despite recent financial challenges, the long-term growth potential and market opportunity in Duchenne muscular dystrophy make this a compelling investment.
The stock exhibits a bullish trend with moving averages in alignment (SMA_5 > SMA_20 > SMA_200). The MACD is positive and contracting, while RSI is neutral at 62.878, indicating no overbought or oversold conditions. The stock is trading near its resistance level (R1: 28.77), suggesting potential for further upward movement.
Positive Phase 3 trial results for Deramiocel, showing significant efficacy in Duchenne muscular dystrophy.
Multiple analyst upgrades with price targets raised to $45-$60, reflecting strong confidence in the company's growth potential.
Progress toward FDA approval with a Type II 6-month review expected by mid-
Investor optimism following a 30% surge in share price after trial results.
Recent financial performance shows no revenue and a net loss of $24.57M in Q3
Broader market uncertainty due to increased global tariffs announced by President Trump.
In Q3 2025, revenue dropped to $0 (-100% YoY), but net income improved to -$24.57M (+95.68% YoY) and EPS increased to -0.54 (+42.11% YoY). Gross margin also dropped to 0 (-100% YoY). While financials are weak, the company is in a pre-revenue phase with significant future growth potential tied to Deramiocel's approval and commercialization.
Analysts are overwhelmingly positive on CAPR, with multiple firms raising price targets significantly (to $45-$60) and maintaining Buy or Overweight ratings. Analysts highlight the strong clinical data, high probability of FDA approval, and substantial revenue potential for Deramiocel, which could reach $1.1B in risk-adjusted net sales by 2030.
